All In Biotech

NDA 217779 · Geron

Rytelo

Imetelstat Sodium · Intravenous

NovelOrphan

CDER novel approval, Jun 6, 2024: To treat low- to intermediate-1 risk myelodysplastic syndromes

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jun 6, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

46

4 Phase 3, 2 recruiting

FAERS reports

186

103 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2026.

1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). ( 1 )

Mechanism: Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), inhibits telomerase enzymatic activity and prevents telomere binding. Increased telomerase activity and human telomerase reverse transcriptase (hTERT) RNA expression have been reported in MDS and malignant stem and progenitor cells. Nonclinical studies showed imetelstat treatment led to reduction of telomere length, reduction of malignant stem and progenitor cell proliferation, and induction of apoptotic cell death.

Therapeutic areas: Hematology and blood cancers · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • RYTELO · IMETELSTAT SODIUM EQ 47MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
  • RYTELO · IMETELSTAT SODIUM EQ 188MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Imetelstat" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • platelet count decreased29
  • haemoglobin decreased27
  • thrombocytopenia24
  • cytopenia20
  • neutropenia17
  • neutrophil count decreased11
  • white blood cell count decreased10
  • infusion related reaction9
  • death8
  • dyspnoea7
  • pancytopenia7
  • drug ineffective6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202441
2025113
202632

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rytelo (Imetelstat Sodium)

2024 spending

$1.7M

Beneficiaries

22

55 claims

Per beneficiary

$78,538

$3,704.76 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,727,835

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Geron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.